Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. 3D-Bioprinted Vascularized Tissue Constructs

3D-Bioprinted Vascularized Tissue Constructs

Printers capable of generating functional capillary networks within lab-grown organs.
Back to HelixView interactive version

3D-bioprinted vascularized tissue constructs use advanced bioprinters that can simultaneously deposit living cells and sacrificial materials (inks that are later removed) to create intricate, patent vascular networks within engineered tissues. This hardware breakthrough solves the fundamental diffusion limit problem in tissue engineering, where cells more than a few hundred micrometers from a blood supply cannot survive due to oxygen and nutrient limitations. By creating functional capillary networks, these systems enable the creation of thick, viable tissue grafts and pave the way for fully functional lab-grown organ replacements.

This innovation addresses the critical challenge in tissue engineering where creating large, thick tissues has been impossible without vascularization. Traditional tissue engineering approaches could only create thin layers of cells, limiting applications. By enabling vascularization, bioprinting can create tissues of meaningful size and complexity. Companies like Organovo, 3D Bioprinting Solutions, and research institutions are developing these capabilities.

The technology is essential for advancing toward functional organ replacement, where creating tissues with integrated blood supply is a fundamental requirement. As the technology improves, it could enable the creation of transplantable organs, addressing the critical shortage of donor organs. However, creating functional, long-lasting vascular networks, ensuring proper integration with host vasculature, and scaling to full-size organs remain significant challenges. The technology represents a major advance in tissue engineering capabilities, but requires continued development to achieve the complexity and functionality needed for organ replacement. Success could transform transplantation medicine by providing an unlimited supply of compatible organs, but the path from current capabilities to functional organ replacement is long and requires many additional advances.

TRL
4/9Formative
Impact
5/5
Investment
4/5
Category
Hardware

Related Organizations

Prellis Biologics

United States · Startup

95%

Specializes in holographic laser printing to create vascularized tissue scaffolds at high speed.

Developer
Tel Aviv University (Tal Dvir Lab)

Israel · University

95%

Research lab that successfully 3D printed a vascularized engineered heart using a patient's own cells.

Researcher
Volumetric

United States · Company

95%

Developed the 'Print to Perfusion' technology for creating vascularized tissues; acquired by 3D Systems.

Developer
Wyss Institute for Biologically Inspired Engineering logo
Wyss Institute for Biologically Inspired Engineering

United States · Research Lab

95%

Developed the SWIFT (Sacrificial Writing into Functional Tissue) method for 3D printing vascular channels in living matrices.

Researcher
Aspect Biosystems logo
Aspect Biosystems

Canada · Company

90%

Uses microfluidic 3D bioprinting technology to create bioprinted therapeutics, partnering with Novo Nordisk.

Developer
Fluicell

Sweden · Company

85%

Provides single-cell bioprinting platforms (Biopixlar) capable of creating detailed tissue microenvironments.

Developer
Poietis logo

Poietis

France · Company

85%

Uses laser-assisted bioprinting (LAB) to print living cells with single-cell resolution.

Developer
Advanced Solutions Life Sciences

United States · Company

80%

Creators of the BioAssemblyBot, a robotic arm bioprinter capable of complex vascular workflows.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Hardware
Hardware
Organ Bioprinting Systems

Large-format bioprinters fabricating perfusable organ scaffolds.

TRL
4/9
Impact
5/5
Investment
5/5
Hardware
Hardware
Normothermic Organ Perfusion Bioreactors

Ex vivo life-support systems that repair and rejuvenate organs before transplantation.

TRL
7/9
Impact
4/5
Investment
4/5
Applications
Applications
Regenerative Scaffolds & Smart Biomaterials

Dynamic, self-healing scaffolds seeded with autologous stem cells.

TRL
6/9
Impact
4/5
Investment
3/5
Hardware
Hardware
Organ-on-Chip & Multi-Organ Microphysiological Systems

Microfluidic platforms simulating aging and rejuvenation pathways.

TRL
6/9
Impact
4/5
Investment
3/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions